GeNeuro SA

GNRO

Company Profile

  • Business description

    GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).

  • Contact

    3 chemin du Pre-Fleur
    Plan-les-Ouates
    Geneva1228
    CHE

    T: +41 225524800

    https://www.geneuro.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    19

Stocks News & Analysis

stocks

Palantir earnings: Blockbuster growth amid high expectations

We raise our fair value estimate off the back of earnings.
stocks

ResMed earnings: Solid showing from ASX healthcare winner

Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
stocks

Is this the $80 billion elephant Warren Buffett has been waiting for?

Morningstar’s Greg Warren says Berkshire may have little choice but to take a hard look at this huge potential acquisition.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,088.2059.400.66%
CAC 407,621.0410.97-0.14%
DAX 4023,846.0788.380.37%
Dow JONES (US)44,111.7461.90-0.14%
FTSE 1009,142.7314.430.16%
HKSE24,902.53169.080.68%
NASDAQ20,916.55137.03-0.65%
Nikkei 22540,529.1220.42-0.05%
NZX 50 Index12,905.1228.080.22%
S&P 5006,299.1930.75-0.49%
S&P/ASX 2008,823.5053.100.61%
SSE Composite Index3,617.6034.290.96%

Market Movers